B+
Bull case
25%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
ABEO
Abeona TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Higher recognized treatments across the expanding center network could demonstrate repeatable ZEVASKYN demand. Q2 revenue growth and $146.8 million of June 30 cash and short-term investments provide evidence of launch progress and some financial flexibility.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -2.2.
What can break
ABO-701 remains preclinical; FDA feedback, studies, or manufacturing work could change the 2027 IND timetable. [#SEC-8K-2026-06-04]
Momentum
16
Value
44
Sentiment
82
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.50 · Bull $9.00 · Bear $2.30Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $18.88
Why
Momentum16 · Δ7d +3.3
Value44 · Δ7d -0.0
Sentiment82 · Δ7d -2.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -2.2.
Contradictions & invalidation
- • ABO-701 remains preclinical; FDA feedback, studies, or manufacturing work could change the 2027 IND timetable. [#SEC-8K-2026-06-04]
- • Cash consumption, continued losses, and potential future financing or dilution remain material for a small-cap biotech. [#SEC-8K-2026-08-13]
- • Manufacturing failures can leave treated patients without recognized revenue, while patient onboarding and surgery remain operationally complex.
Catalyst clock
2026-12-31
Medicare add-on payment begins to affect access
Lead driver: Sentiment · See AI snapshot
Momentum
16
8% active weight
Current posture
7d trendSoftening
Δ7d
+3.3
Δ21d
-0.8
Value
44
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
82
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.2
Δ21d
+6.2
Why this grade
Composite grade B. Momentum 15.5 / Value 43.7 / Sentiment 82.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.30
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$251.61M
Beta
1.17
Shares Out
57.18M
P/E (TTM)
4.7
P/S (TTM)
707.20
P/FCF (TTM) · Derived
-3.00
Rev YoY
+2745.0%
EPS YoY
-120.7%
Gross Margin
+47.2%
Op Margin
+17289.3%
Net Debt
-$166.44M
Current Ratio
6.63
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data